Abbott Laboratories Inc. is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain that were announced at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas.
The US Food and Drug Administration approved Proclaim XR for chronic pain in September. Proclaim XR delivers the BurstDR waveform, which is designed to manage pain with low doses of stimulation and uses a battery that lasts up to 10 years without recharging